ArticleFrontiers in endocrinology2025
Effect of timely diagnosis and treatment on growth and body proportionality of children with congenital hypothyroidism.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Growth and Neurodevelopmental Outcomes of Children With Congenital Hypothyroidism Identified Through Dried Blood Spot Newborn Screening at a Tertiary Care Hospital in Pakistan.Endocrinology, diabetes & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Congenital hypothyroidism (CH) is a preventable cause of growth and neurodevelopmental deficits. In India, lack of universal newborn screening (NBS) delays diagnosis. This study examines how treatment timing influences growth, nutrition, and body proportionality in children with CH. Methods: This cross-sectional study included 66 children with CH, aged under 5 years, receiving Levothyroxine(LT4) therapy for one year. Age and sex-matched 64 healthy children were also enrolled. Children with CH were stratified into early-treated (<3months) and late-treated (>3months) groups. Anthropometric measurements were converted to Z-scores using WHO standards. Body proportionality was assessed using: height-arm span difference, upper segment-to-lower segment (US: LS) ratio, Manouvrier's Indice Skélique (MIS). MIS classifies skeletal proportions as brachyskelia (short legs, long trunk; score ≤84.9), mesatyskelia (intermediate; 85.0-89.9), and macroskelia (long legs, short trunk; ≥90). Results: Children with CH had significantly lower height-for-age (HAZ -2.31 ± 1.32 vs. -0.41 ± 0.96), weight-for-age (WAZ -1.98 ± 1.41 vs. -0.36 ± 1.02), and head circumference-for-age (HCZ -1.52 ± 1.28 vs. -0.21 ± 0.89) Z-scores compared with healthy controls (all p < 0.001). Stunting (HAZ < -2 SD) was present in 53% of children, while underweight (WAZ < -2 SD) was observed in 36.4%. Late-treated children had a higher prevalence of severe stunting (67.7% vs. 11.4%), severe underweight (29.0% vs. 2.9%), and microcephaly (35.5% vs. 8.6%) compared with early-treated children (p < 0.05). Disproportionate stature was observed in 71.0% of late-treated children compared with 42.9% of early-treated children (p < 0.05). US: LS ratio and Manouvrier's Index further confirmed greater skeletal disproportionality in late-treated children compared with early-treated children (p < 0.05). Conclusions: Delayed treatment in CH significantly impairs growth, increases skeletal disproportionality, and adversely affects neurocranial development. Early initiation of therapy-ideally within the first 3 months-is essential. These findings highlight the need for newborn screening in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.